BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.560
+0.550 (27.36%)
At close: Mar 3, 2025, 4:00 PM
2.260
-0.300 (-11.72%)
Pre-market: Mar 4, 2025, 8:00 AM EST
BioCardia Employees
As of December 31, 2023, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees decreased by 16 or -44.44% compared to the previous year.
Employees
20
Change (1Y)
-16
Growth (1Y)
-44.44%
Revenue / Employee
$3,550
Profits / Employee
-$386,100
Market Cap
11.74M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BCDA News
- 4 days ago - BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 18 days ago - BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - GlobeNewsWire
- 5 weeks ago - BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 3 months ago - BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - GlobeNewsWire
- 3 months ago - BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 6 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire